May 15, 2009, 06.32 PM | Source: CNBC-TV18
Dr Reddys Laboratories is to announce its fourth quarter FY09 results. According to CNBC-TV18 estimates, its consolidated, US GAAP (But Q4 nos will IFRS will be IFRS and not US GAAP) .
Its net sales is seen up 24% at Rs 1640 crore versus Rs1325 crore.
Its operating profit is seen up at Rs 225 crore versus Rs 172.5 crore.
Its OPM is seen at 14% versus 13%.
Its net profit is expected to go up 32% at Rs 137 crore versus Rs 102.8 crore.
Key factors to watch for:
Write offs from Betapharm expected in the range of Rs 200- 250 crore (not included in the estimates Final PAT figure may actually be loss because of this ) related to intangible impairment in Germany
-Generic Imitrex to contribute about Rs 150 Cr to the top line and Rs 40-50 crore to the net profits